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Abstract
Background: Fine control of lysosomal degradation for limited processing of internalized antigens is a hallmark of
professional antigen presenting cells. Previous work in mice has shown that dendritic cells (DCs) contain lysosomes with
remarkably low protease content. Combined with the ability to modulate lysosomal pH during phagocytosis and
maturation, murine DCs enhance their production of class II MHC-peptide complexes for presentation to T cells.
Methodology/Principal Findings: In this study we extend these findings to human DCs and distinguish between different
subsets of DCs based on their ability to preserve internalized antigen. Whereas DCs derived in vitro from CD34+
hematopoietic progenitor cells or isolated from peripheral blood of healthy donors are protease poor, DCs derived in vitro
from monocytes (MDDCs) are more similar to macrophages (MWs) in protease content. Unlike other DCs, MDDCs also fail to
reduce their intralysosomal pH in response to maturation stimuli. Indeed, functional characterization of lysosomal
proteolysis indicates that MDDCs are comparable to MWs in the rapid degradation of antigen while other human DC
subtypes are attenuated in this capacity.
Conclusions/Significance: Human DCs are comparable to murine DCs in exhibiting a markedly reduced level of lysosomal
proteolysis. However, as an important exception to this, human MDDCs stand apart from all other DCs by a heightened
capacity for proteolysis that resembles that of MWs. Thus, caution should be exercised when using human MDDCs as a
model for DC function and cell biology.
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Introduction
The role of macrophages (MWs) in the acquisition and
degradation of exogenous material is well established throughout
the phylogeny of metazoans [1]. Yet in vertebrates such complete
degradation is inconsistent with the production of peptides of
sufficient length (13–17 amino acids) to bind class II MHC
molecules for presentation to T cells [2,3]. Antigen processing
requires limited degradation of proteins and preservation of cognate
T cell epitopes [4]. It was recently demonstrated in mice that the
most efficient antigen presenting cells, dendritic cells (DCs) and B
cells, are distinguished from MW in their ability to greatly
attenuate lysosomal degradation of internalized antigen [5,6]. This
is mechanistically mediated through a fine control of lysosomal
proteolytic activity that was previously unappreciated. Both DCs
and B cells, in vitro and in vivo, exhibit a remarkably low level of
lysosomal protease expression. DCs furthermore control degrada-
tion by modulation of lysosomal pH that attenuates proteolysis in
the immature state and moderately increases the level of
proteolysis with maturation [7]. Additionally, in the case of
phagocytosed antigens it has been demonstrated that NOX2
contributes to an increase in the alkalinity of the phagolysosome,
further limiting proteolysis [8,9].
Both mouse and human DCs found in vivo have been
categorized into a number of subsets based on phenotypic and
functional differences [10,11]. Moreover, several methods have
been developed for deriving subsets of human DCs in vitro from
precursor cells, most commonly from CD34
+ hematopoietic
precursors (CD34DCs) and monocytes (MDDCs). CD34DCs
have the advantage of being derived from an early hematopoietic
precursor (analogous to bone marrow-derived DCs [BMDCs] in
mice), though the number of starting cells can be limiting. On the
other hand, monocytes are an abundant cell type from which large
numbers of MDDCs can be cultured, though they are more
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MW linage. In the study that follows we extend the initial
investigations of lysosomal function in mouse DCs to both in vivo-
and in vitro-derived DCs of human origin.
Results
MDDCs are distinguished from other DC subsets in
having high lysosomal protease content
We first investigated the relative abundance of representative
lysosomal proteases in human monocyte-derived MWs, MDDCs,
and CD34DCs. These cells were cultured as previously described
[12,13] and cell-free extracts were prepared for immunoblot
analysis of the proteases and c-interferon-inducible lysosomal thiol
reductase (GILT). Surprisingly we found that cathepsins (cat) B, D,
L and S, asparginyl endopeptidase (AEP), and GILT were in near
equal abundance in MWs and immature MDDCs, slightly less
abundant in populations of mature MDDCs (produced by
overnight treatment with LPS), with only trace amounts present
in CD34DCs (Fig. 1A). Overexposure of the blots revealed that
these enzymes were present in CD34DCs, though in markedly
lower abundance (Fig. 1B).
To assess whether the differences in lysosomal protease
expression could be accounted for at the transcriptional level,
we performed quantitative RT-PCR on RNA samples from
MWs, MDDCs, and CD34DCs using primers for catB, catD,
catL, catS, AEP, and GILT. The transcriptional profiles mostly
segregated into two distinct groups: the MWs and immature
MDDCs with a high relative level of protease transcription and
the immature and mature CD34DCs with a low level of
transcription (Fig. 1C). Indeed, a general correlation between
the abundance of protease transcripts and protein for these two
groups was evident. The transcriptional profile for the mature
MDDCs, however, was not proportional to the protein profile,
as the level of transcription was closer to that of the CD34DCs,
while the amount of protein present more closely matches the
MWsa n di m m a t u r eM D D C s .T h er e l a t i v ea b u n d a n c eo f
protease expression at the protein level in mature MDDCs
likely reflects the fact that transcription of many genes is
reduced following DC maturation but that lysosomal proteases
are relatively long-lived.
Given the dramatic differences in protease expression between
DCs derived in vitro from monocytes and from CD34
+ hemato-
poietic progenitor cells, we assessed the protease expression profile
of dendritic cells taken ex vivo from human blood. Cell-free extracts
were prepared from myeloid DCs (MDCs) and plasmacytoid DCs
(PDCs) that were purified from the blood of healthy donors as
previously described [14]. Both MDCs and PDCs exhibited levels
of protease expression that were very low, comparable to
CD34DCs, and in marked contrast to MWs (Fig. 1D).
Figure 1. MDDCs are abundant in lysosomal proteases compared to other DCs. (A) Immature (i-) and mature (m-) MDDCs are comparable
to MWs in protease protein abundance as assessed by immunoblot of cell lysates. By contrast, immature and mature CD34DCs exhibit remarkably
lower expression levels of protease protein than either MWs or MDDCs. (B) Overexposure of the blots from (A) reveals that the enzymes are present in
CD34DCs, though in strikingly diminished amounts. (C) Quantitative RT-PCR shows that MWs and MDDCs are also distinct in having a high quantity of
transcripts for the enzymes compared to CD34DCs. Data are displayed as ‘‘fold-greater’’ than immature CD34DCs. (D) PDCs and MDCs taken ex vivo
from healthy donors also display markedly low levels of lysosomal protease expression. c-tubulin was used as loading control.
doi:10.1371/journal.pone.0011949.g001
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but not always, contain a low level of lysosomal proteases. While
human CD34DCs, PDCs and MDCs share the protease
expression characteristics of murine BMDCs and DCs from
mouse secondary lymphoid organs, human DCs derived from
monocytes are distinguished by a protease expression profile
similar to that of MWs with whom they share a direct precursor
(i.e., the monocyte).
MDDCs exhibit high levels of lysosomal proteolysis in
vitro compared to CD34DCs
We next determined whether the observed differencesin protease
expression were reflected in the proteolytic capacity of MDDCs and
CD34DCs. Initial results from in vitro degradation assays of OVA
protein suggested that MDDCs hydrolyzed proteins at a level
matching that of MWs, while CD34DCs were attenuated in this
capacity (Fig. 2A). Lysosomal proteolysis by these cells was
quantitatively assessed using an in vitro kinetic degradation assay
which demonstrated that immature MDDCs degraded the protein
substrate at a rate equivalent to that of MWs, while immature and
mature CD34DCs exhibited a 17-fold and 28-fold lower level of
degradation than MWs, respectively (Fig. 2B). The mature MDDCs
displayed an intermediate rate of degradation that was 2-fold less
than MWs. Thus the high level of protease expression in MDDCs
was reflected in vitro by greater degradative capacity.
As described below, developmental upregulation of protease
expression was evident in both MDDCs and MWs derived in vitro
from monocytes. Cell-free extracts were prepared from monocyte
cultures at defined intervals as the cells differentiated into either
MDDCs or MWs. Using catB as a surrogate for the proteases,
immunoblotting of these samples revealed that at an early time
point of differentiation (day 2) the level of lysosomal protease
expression was fairly low (Fig. 2C). CatB expression cumulatively
increased in the MWs on days 4 and 6. In MDDC cultures the level
of protease expression on day 4 was roughly equivalent to day
6M Ws. Maturation of the MDDCs and analysis of the cell extracts
on day 6 demonstrated a decrease in protease expression. Again,
the level of protease expression correlated with degradative
capacity as measured by OVA degradation in vitro (Fig. 2D).
MDDCs and CD34DCs are comparable in lysosomal
degradation of non-protein substrates
The initial investigation of lysosomal degradation in DCs of mice
demonstrated that, in contrastto proteolysis, DCs were comparable
to MWs in lysosomal degradation of non-protein substrates [5].
Indeed, this finding is consistent with the observation that post-
translational modifications of proteins only rarely contribute to the
cognate T cell epitopes bound to class II MHC [15,16,17], perhaps
because these modifications are removed in lysosomes. We
therefore investigated whether the attenuated proteolytic capacity
of human CD34DCs was due to an overall decrease in lysosomal
hydrolytic activity or whether it was protease-specific. Cell-free
extracts were prepared from MWs, MDDCs, and CD34DCs and
were tested against substrates specific for the activity of lysosomal
acid phosphatase, b-glucuronidase, and a-mannosidase. In contrast
to the marked difference in protease activity between MDDCs and
CD34DCs, these other lysosomal hydrolases were comparable in
activity between the two DC subsets (Fig. 3A). Though the greatest
difference in hydrolytic activity was seen between the mature
CD34DCs and the immature MDDCs when assaying for b-
glucuronidase activity, this difference was at most 5-fold,
substantially less then the 28-fold difference in protease activity
between these two DC types (Fig. 3B). The difference in lysosomal
hydrolytic capacity between MDDCs and CD34DCs was therefore
predominantly limited to proteolysis, analogous to our previous
findings using bone marrow-derived mouse DCs vs. mouse
macrophages [5].
Figure2.MDDCsexhibithigh lysosomalproteaseactivityinvitro
comparedtoCD34DCs.(A)Celllysates preparedfromculturesofMWs,
MDDCs, and CD34DCs were incubated together with OVA in either
degradation reaction buffer (pH 4.5) or control buffer (pH 7.4). A sample
containing OVA in reaction buffer with no lysate was loaded in the first
lane as a non-degraded sample. Partial degradation of OVA by MWs and
MDDCs is evident while no degradation by CD34DCs is seen. (B)
Quantitation of the rate of degradation by these cells using a self-
quenching fluorescent protein substrate demonstrates that immature (i-)
MDDCs are equivalent to MWs in proteolytic capacity, mature (m-)
MDDCs are 2-fold less proteolytic than MWs, while i-CD34DCs and m-
CD34DCs are 17- and 28-fold less proteolytic than MWs, respectively. (C)
Cell lysates were prepared from monocyte cultures as they differentiated
into either MDDCs or MWs and were analyzed by immunoblot for catB.
CatB expression in MDDCs culminates at day 4 and is diminished
following maturation on day 5 and analysis on day 6. MWs exhibit a
steadyincrease in catB expression from a lowlevel atday2 to a high level
at day 6. (D) Cell lysates of culture samples from (C) were assessed for
degradative capacity by incubation with OVA in either reaction buffer
(pH 4.5) or control buffer (pH 7.4). Degradation at pH 4.5 correlates with
protease expression levels. Relative fluorescence units (RFU).
doi:10.1371/journal.pone.0011949.g002
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preserved by CD34DCs
To determine whether antigen was degraded in intact MDDCs
and CD34DCs as well as in cell-free preparations, we developed
an assay for assessing protein degradation in live DCs. MDDCs
and CD34DCs were pulsed for 2 hrs with immune complexes of
HRP and polyclonal anti-HRP antibodies, washed, and then
returned to culture for 24–48 hr in the presence or absence of a
maturation stimulus. After these incubations, the cell-associated
HRP activity was determined using a kinetic assay. Intriguingly,
while the immature MDDCs displayed an expected loss of HRP
activity due to lysosomal degradation, the MDDCs that were
matured showed only a modest level of HRP degradation (Fig. 4A
and 4B). This was likely due to the decrease in lysosomal protease
content as well as an increase in lysosomal pH (see below) that
occurred during MDDC maturation. Conversely, even 48 hours
after loading the immature CD34DCs, the internalized HRP
displayed a minimal amount of degradation. Maturation of the
CD34DCs resulted in an increase in lysosomal degradation,
presumably reflecting a decrease in lysosomal pH that accompa-
nies maturation (see below).
In an independent set of experiments we measured lysosomal
pH of MDDCs and CD34DCs. These studies revealed that
lysosomal acidification in CD34DCs was regulated in response to
maturation stimuli, as found previously for mouse bone marrow-
derived DCs (Fig. 4C). In the immature state, the lysosomes of
human CD34DCs exhibited an elevated pH (,5.6). Given the
strict acid requirement for lysosomal proteolytic activity, such an
elevated lysosomal pH would result in a significant reduction in
the activity of the proteases present. Following LPS-induced
maturation of these cells, lysosomal pH dropped closer to the pH
optimum of most lysosomal hydrolases (,4.5) therefore providing
an environment more conducive to proteolysis. MDDCs exhibited
a low lysosomal pH in the immature state (,4.5), similar to that
found in macrophages (pH 4.7–4.8 [18]) and most other cells.
Two general conclusions can be inferred from this set of data.
First, as in the case of murine DCs, human DCs also exhibit a
markedly reduced capacity for antigen proteolysis. Second, there is
an important exception to this conclusion. MDDCs, the widely
used model for DCs derived directly from monocytes, are indeed
far more reminiscent of macrophages with respect to their capacity
for lysosomal proteolysis than they are similar to DCs, either
human or mouse, conventional or plasmacytoid.
Discussion
DCs were originally identified by their remarkable capacity to
stimulate antigen-specific T cell proliferation [19,20,21]. Investi-
gation into the mechanisms underlying this capacity revealed that
these cells utilize a number of cell biological specializations to
achieve this end [4,22]. In addition to the phenotypic changes that
occur with DC maturation and the tight regulation of MHC
expression and distribution, recent work has shown that these cells
are acutely distinguished from other myeloid leukocytes by
specializations in antigen handling and processing within lyso-
somes [23,24].
Consistent with the discovery of restricted lysosomal proteolysis
in DCs of mice, lysosomes of human DCs taken from blood or
derived from hematopoietic progenitors harbor a protease poor,
antigen-preserving environment. The combination of low protease
content and attenuated lysosomal pH in immature CD34DCs
leads to limited degradation of internalized antigen. Concomitant
with maturation, lysosomal pH drops and degradation increases.
Thus, in addition to well-established mechanisms for antigen
acquisition and T cell stimulation, human DCs also utilize
mechanisms for antigen preservation that are similar to those of
mice.
DCs derived in vitro from human monocytes are set apart from
other DCs by resembling MWs in lysosomal degradative capacity.
Figure 3. MDDCs and CD34DCs are similar in activity of other
lysosomal hydrolases. (A) Cell lysates made from cultures of MWs,
MDDCs, and CD34DCs were incubated together with fluorescent
substrates specific for acid phosphatase, a-mannosidase, and b-
glucuronidase in either reaction buffer (pH 4.5) or control buffer
(pH 7.4). After a 60-minute reaction, detection of the reaction product
was measured with a fluorescence spectrophotometer. (B) Compendi-
um of lysosomal hydrolase activity measurements relative to MWs.
While the non-protease acid hydrolases show a similar magnitude of
activity in MDDCs and CD34DCs, the differences in proteolysis between
the two subsets are accentuated. Immature (i-) and mature (m-) DCs;
relative fluorescence units (RFU).
doi:10.1371/journal.pone.0011949.g003
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current data indicate that in steady state conditions dendritic cells
and monocytes arise from a common precursor cell, while under
inflammatory conditions dendritic cells differentiate directly from
newly immigrated monocytes [25,26,27]. Our data suggest that
monocytes have already engaged a developmental program that
Figure 4. Degradation of internalized proteins by intact MDDCs and CD34DCs. (A) MDDCs (top) or CD34DCs (bottom) were pulse-chased
with HRP immune complexes. Immediately after chase (0 h) an aliquot of the cells was measured for HRP activity. The remaining cells were placed
back into culture for 24 h (MDDCs) or 48 h (CD34DCs) either in the presence or absence of a maturation stimulus; culture times corresponded to the
minimum required to achieve complete (.90%) maturation for each cell type. After this re-culture, the cells were measured for HRP activity. DCs not
pulsed with HRP immune complexes (No HRP) were used as negative control and make clear that endogenous peroxidase activity is negligible
compared to HRP activity. HRP activity in immature MDDCs is reduced by .50% after 24 h in culture, whereas maturation of the MDDCs attenuates
the degradation of HRP. In contrast, even after 48 h in culture, HRP activity in immature CD34DCs remains nearly equivalent to the freshly loaded
cells. Maturation of the CD34DCs leads to 50% reduction in HRP activity after 48 h. (B) Maturation of MDDCs (top) or CD34DCs (bottom) that were
loaded with HRP immune complexes was assessed by CD86 expression. Immature DCs analyzed either immediately after pulse-chase with HRP
immune complexes or following re-culture of the pulse-chased cells were CD86
lo. DCs that were matured in culture were CD86
hi. (C) Lysosomal pH of
MDDCs and CD34DCs was measured using the pH-sensitive lysosomotrophic dye LysoSensor Yellow/Blue DND-160. HeLa cells are included as
reference. Whereas lysosomal pH of MDDCs is low in the immature state and rises slightly with maturation, immature CD34DCs have an elevated
lysosomal pH which drops considerably with maturation to a level more conducive to proteolysis. Data are displayed as mean 6 s.e.m. Immature (i-)
and mature (m-) DCs.
doi:10.1371/journal.pone.0011949.g004
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differentiate into DCs they acquire many of the characteristic
phenotypic traits of DCs while also developing MW-like lysosomes.
One can distinguish between different subsets of DCs based on
functional and phenotypic variation [25] and the presence of
highly degradative lysosomes in MDDCs points to a cell biological
specialization that separates this subset from other DCs.
Regardless of subset, DCs are collectively set apart from other
cell types by an exquisite capacity for antigen acquisition and T
cell stimulation. In this regard the tremendous rate of macro-
pinocytosis by MDDCs coupled with very high expression of class
II MHC may partly account for their ability to rescue some
peptides for presentation to T cells despite the very proteolytic
nature of their lysosomes [12]. Additionally, in vivo these cells are
found predominantly at active inflammatory sites and may be
particularly well suited for the acquisition, processing, and
presentation of bulky particulate and microbial antigens more so
than soluble proteinaceous antigens. This contrasts with other DC
subsets which, while exhibiting a similar capacity for degradation
of non-proteinaceous material, would easily preserve T cell
epitopes from either a particulate or soluble source. Indeed, our
previous studies using murine DCs demonstrate that they have a
reduced capacity for the degradation of yeast as compared to
murine macrophages [7].
As highly degradative cells, MWs have a clear function in innate
immunity, in wound healing, and in the effector arm of adaptive
immunity where they participate in antigen clearance and in
microbial killing and digestion. Native immunologically relevant
antigens consist of biological macromolecules that must be
degraded prior to presentation to T cells. Prima facie it is
counterintuitive that the antigen presenting cells best equipped
to stimulate T cells are poorly degradative, yet this underscores
that partial degradation of antigens is an unequivocal requirement
for the production of cognate T cell epitopes [23]. Indeed, though
degradative cells have an ancient role in wound healing and innate
immunity, the onset of adaptive immunity drove the need for a
specialized cell type capable of preserving small peptides in the
context of otherwise degradative lysosomes [28,29].
Materials and Methods
Antibodies
The following antibodies were used for western blotting: mouse
anti-human CatB (Serotec), rabbit anti-human CatD (Dako), goat
anti-human CatL (Santa Cruz Biotechnology), rabbit anti-human
CatS (CalBioChem), sheep anti-human AEP (R&D Systems),
rabbit anti-human GILT (a kind gift of P. Cresswell, Yale
University), and mouse anti-human c-tubulin (Sigma). The anti-
human monoclonal antibodies used for flow cytometry were as
follows: anti-CD1a, -CD11c, -CD86, -CD123, -HLA-DR, and
Lin1 (Lineage cocktail 1, a cocktail of antibodies directed against
CD3, CD14, CD16, CD19, CD20, and CD56) (BDBiosciences).
Cell Isolation and Culture
Human monocytes were isolated from buffy coats of healthy
donors (New York Blood Bank) using RosetteSep Human
Monocyte Enrichment Cocktail (StemCell Technologies) accord-
ing to the manufacturer’s protocol. For MDDC cultures,
monocytes were grown at 1610
6cells/mL in 10 cm bacteriolog-
ical-grade petri dishes (BD Biosciences) in RPMI 1640 supple-
mented with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin, 20 mg/mL gentamicin, (Gibco/Invitro-
gen), 150 ng/mL GM-CSF (Leukine (sargramostim), Bayer
HealthCare Pharmaceuticals), and 25 ng/mL IL-4 (Peprotech)
at 37uC. Immature MDDCs were harvested at day 5. For mature
cells, maturation was induced on day 5 by adding 100 ng/mL
lipopolysaccharide (LPS, Sigma) or DH5a bacteria (Stratagene)
and allowing maturation to proceed for 24 hours.
For monocyte-derived MW cultures, monocytes were grown at
1610
6cells/mL in 10 cm bacteriological-grade petri dishes (BD
Biosciences) in RPMI 1640 supplemented with 10% FBS, 2 mM
L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin,
20 mg/mL gentamicin (Gibco/Invitrogen), and 50 ng/mL M-
CSF (Peprotech) at 37uC. MWs were harvested on day 7.
CD34DCs were derived from CD34
+ hematopoietic progenitor
cells as previously described [13]. Briefly, purified CD34
+ cells
(generously provided by D. Krause, Yale University) were cultured
at a density of 4610
5cells/mL in X-VIVO 10 medium (Cambrex)
supplemented with 2 mM L-glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin (Gibco/Invitrogen), 100 ng/mL GM-
CSF (Leukine (sargramostim), Bayer HealthCare Pharmaceuti-
cals), 20 ng/mL SCF, 2.5 ng/mL TNFa, 0.5 ng/mL TGFb1, and
100 ng/mL Flt3L (Peprotech) at 37uC. After 7–10 days of culture
the clustered cells were purified over a 7.5% BSA density cushion
at 1xg for 30 minutes on ice. The pellets were retrieved and
washed with cold PBS. The cells were then either taken as
immature CD34DCs or were matured by culturing them in the
growth medium supplemented with either 100 ng/mL LPS
(Sigma) or DH5a bacteria (Stratagene) and allowing maturation
to proceed for 48 hours.
Blood MDCs and PDCs were isolated as previously described
[14]. Briefly, mononuclear cells were first isolated from buffy coats
(New York Blood Bank) on a Ficoll-Paque gradient (GE
Healthcare). The samples were enriched for DCs using a negative
selection enrichment cocktail (EasySep Human Pan-DC Pre-
enrichment Kit, StemCell Techologies) according to the manu-
facturer’s protocol. The cells were labeled with Lin1, anti-CD123,
anti-HLA-DR, and anti-CD11c and were sorted by FACS where
the DCs were separated according to their phenotype. MDCs
were Lin1
2, HLA-DR
+, CD11c
+, CD123
2. PDCs were Lin1
2,
HLA-DR
+, CD11c
2, CD123
+.
Preparation of Cell Lysates and Immunoblotting
As many lysosomal proteases are inactivated by alkaline or
neutral conditions [30,31,32], the preparation of cell lysates was
consistently performed in a slightly acidic buffer. The cell-free
extracts were prepared in sucrose buffer (0.25 M sucrose, 20 mM
HEPES, 2 mM EDTA (Sigma), pH 6.5) with 1% Triton X-100
(Sigma).
Gel electrophoresis and coomassie staining were performed
according to standard protocols. Immunoblotting was performed
with the indicated antibodies following SDS-PAGE and transfer to
nitrocellulose filters (Schleicher and Schuell). All secondary
antibodies used for western blotting were conjugated to HRP
and the membranes were developed using an enzymatic
chemiluminescence system (Pierce Biotechnology).
Quantitative RT-PCR
Total RNA was isolated using the RNeasy Kit (Qiagen)
according to the manufacturer’s recommendations. Quantitative
real-time RT-PCR was performed using the QuantiTect SYBR
Green One-Step RT-PCR Kit (Qiagen) and detected with the
Mx3000PH QPCR system (Stratagene). The data were normalized
to the level of GAPDH expression in each individual sample. The
ratio of transcript abundance was calculated using the immature
CD34DC values as a base unit equal to one, thus allowing
for display of the data as ‘‘fold-greater’’ than the immature
CD34DCs.
Lysosomal Proteolysis in DCs
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Studies of lysosomal pH in intact cells were performed using an
acidotrophic probe that selectively partitions into the lysosomal
compartments of living cells. The probe used (LysoSensor Yellow/
Blue DND-160, Molecular Probes) consists of a dye with two
distinct optimal pH sensitivities, which allows dual-emission
measurements and ratiometric quantitation of lysosomal pH. The
procedure used for lysosomal pH measurements was adapted from
the Molecular Probes Handbook [33], previous work by Haugland
and colleagues [34], and previous work by Poole and colleagues
[18]. This approach required a minimum of 18610
6 cells in
suspension. 2610
6 cells were aliquoted out for use as a blank in later
pH measurements. The staining medium containing 5 mM
LysoSensor probe in 5 mL growth medium was allowed to
equilibrate to 37uC in a water bath for 30 minutes. The remaining
16610
6 cells were pelleted and resuspended in the staining medium
and placed at 37uC for 5 minutes. After incubation the cells were
washed once with cold growth medium, twice with cold PBS, and
resuspended in cold PBS. The cells were then divided into 8
separate aliquots and pelleted as was the blank sample separated
above. All subsequent steps were done quickly and on ice.
A series of Mes/HEPES pH buffers were previously prepared
by mixing Mes buffer (50 mM Mes, 50 mM NaCl, 30 mM
Ammonium Acetate, 40 mM Sodium Azide (Sigma), pH 4.0) with
HEPES buffer (50 mM HEPES, 50 mM NaCl, 30 mM Ammo-
nium Acetate, 40 mM Sodium Azide (Sigma), pH 7.5) to achieve
buffers of varying pH, ranging from pH 4.0 to pH 7.4.
Five of the LysoSensor-labeled aliquots were used for lysosomal
pH calibration and were each resuspended in a Mes/HEPES
variable pH buffer with one of the following levels of acidity:
pH 4.0, pH 4.5, pH 5.0, pH 5.5, and pH 6.0. The remaining
aliquots were resuspended in Mes/HEPES buffer, pH 7.4. This
first resuspension in Mes/HEPES buffer was used as a wash and
after centrifuging the aliquots, each was resuspended in 2 mL
(1610
6 cells/mL) of the corresponding Mes/HEPES buffer.
Two minutes prior to fluorescence measurements of the
samples, nigericin and monensin (CalBioChem) were added to a
final concentration of 10 mM to the aliquots used for pH
calibration. This allowed lysosomal pH to equilibrate with the
Mes/HEPES buffer and facilitated the creation of a standard
curve correlating lysosomal pH with the magnitude of fluorescence
emission.
Fluorescence intensity of all samples was measured with a
fluorescence spectrophotometer (Perkin Elmer) at an excitation
wavelength of 360 nm and at two emission wavelengths: 451 nm
and 518 nm. The blank sample was used for background
subtraction at all wavelengths. Using the data from the pH
calibration samples, a standard curve was calculated by plotting
(em451/em518) vs. pH. This standard curve was used to back-
calculate the lysosomal pH of the experimental samples from their
emission values.
In vitro Protein Degradation Assays
Protein degradation assays were developed in house to assess the
proteolytic capacity of lysates from different cell types. Ovalbumin
(OVA; CalBioChem) was used for degradation assays at a
concentration of 0.5 mg/mL and cell lysates at a concentration
of 1 mg/mL. Reactions were performed in degradation reaction
buffer (0.1 M citrate, 1 mM EDTA, 2 mM DTT, 1% Triton X-
100 (Sigma), pH 4.5) or control buffer (0.1 M Tris, 1 mM EDTA,
2 mM DTT, 1% Triton X-100 (Sigma), pH 7.4) at 37uC for 30 or
60 minutes. Samples were separated by SDS-PAGE and visualized
by coomassie staining.
Real-time degradation assays were performed using self-
quenching fluorophore-conjugated casein protein (BODIPY TR-
X casein, Molecular Probes). Reactions proceeded in degradation
reaction buffer (0.1 M citrate, 1 mM EDTA, 2 mM DTT, 1%
Triton X-100 (Sigma), pH 4.5) at 37uC. The labeled casein was
used at a concentration of 50 mg/mL and cell lysates were used at
0.25 mg/mL. Fluorescence intensity data was gathered at 10-
second intervals using a plate reading fluorescence spectropho-
tometer (Molecular Devices) with an excitation wavelength of
589 nm and emission wavelength of 617 nm.
Other Acid Hydrolase Activity Assays
The following hydrolase substrates were used at concentrations
of 6 mM: 4-methylumbelliferyl-phosphate for acid phosphatase
activity, 4-methylumbelliferyl-b-D-glucuronide for b-glucuroni-
dase activity, and 4-methylumbellifery-a-D-mannopyranoside
(Sigma) for a-mannosidase activity. Cell lysates were used at a
concentration of 0.5 mg/mL in degradation reaction buffer
(0.1 M citrate, 1 mM EDTA, 1% Triton X-100 (Sigma),
pH 4.5) or control buffer (0.1 M Tris, 1 mM EDTA, 1% Triton
X-100 (Sigma), pH 7.4). Reactions proceeded at 37uC for 60
minutes and were stopped with 0.4 M carbonate buffer (pH 9.0).
Fluorescence intensity was measured on a fluorescence spectro-
photometer (Perkin Elmer) with an excitation wavelength of
365 nm and emission wavelength of 450 nm.
Endocytosis of HRP Immune Complexes and HRP Activity
Assays
HRP immune complexes were formed by incubation of HRP or
FITC-HRP (Roche Applied Science) with rabbit anti-HRP
(Jackson ImmunoResearch Laboratories) at a mole:mole ratio of
1 mol HRP to 6.8 mol anti-HRP. DCs were pulsed with the 5 mg/
mL HRP immune complexes for 2 hours, washed three times and
chased for 30 minutes.
The immune complex-loaded cells were split into four different
samples. The first sample was assessed for maturation markers by
FACS and the second was used for an HRP activity assay as
detailed below. The third and fourth samples were placed back
into culture with either DC growth medium alone or DC growth
medium plus a maturation stimulus (LPS or DH5a bacteria). After
24 hours (MDDCs) or 48 hours (CD34DCs) of incubation the
samples were assessed for maturation markers by FACS and used
for HRP-activity assay.
For measurement of HRP activity, DCs loaded with HRP-ICs
were washed three times with PBS and dispensed (in 100 mL PBS)
into microtiter plates (BDBiosciences). To each well 100 mL TMB
substrate (3, 39,5 ,5 9-tetramethylbenzidine, Pierce Biotechnology)
was added and OD(650) absorbance readings were acquired for
each well at 10 second intervals using a plate-reading UV/Vis
spectrophotometer (Molecular Devices).
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